Vincerx Pharma is a clinical-stage biopharmaceutical company focused on utilizing its development and oncology capabilities to develop therapies intended to address unmet medical needs for the treatment of cancer. Co.'s pipeline consists of enitociclib and a proprietary modular bioconjugation platform, which includes a small molecule drug-conjugate, VIP236 and preclinical antibody drug-conjugates, VIP943 and VIP924. Co. had been granted an exclusive, royalty-bearing, worldwide license under certain Bayer AG patents and know-how to develop, use, manufacture, commercialize, sublicense, and distribute multiple clinical and preclinical stage compounds. The VINC YTD return is shown above.
The YTD Return on the VINC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether VINC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VINC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|